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Summary 
CD2, a cell surface glycoprotein expressed on T  cells and natural killer cells, can couple to sig- 
naling pathways that result in T  cell proliferation. An Src-like protein tyrosine kinase, p50  ok, 
coprecipitates with CD2, and perturbation of CD2 by monoclonal antibodies results in an in- 
crease in the activity of p56  kk, suggesting that an interaction with p56  l~k contributes to CD2- 
mediated  signaling.  Herein,  we  investigate  the  mechanism  by which  CD2  associates  with 
p561ok. We demonstrate that CD2 and p56  l~k associate when coexpressed in nonlymphoid cells, 
that  this  association requires  the  cytoplasmic domain  of CD2,  and  that  the  SH3  domain  of 
p561ok mediates its interactions with CD2. Using truncation mutants of CD2, we identify two 
regions in the cytoplasnfic domain of CD2 involved in binding p56  kk. Each region contains a 
proline-rich sequence that, in the form of a synthetic peptide, directly binds p56  lck. Thus, pro- 
line-rich sequences in the cytoplasmic domain of CD2 allow this transmembrane receptor to 
bind to the SH3 domain of p561ok. 
variety of receptor-ligand interactions occur when T 
ymphocytes recognize and respond to antigenic pep- 
tides  bound  to  MHC  molecules on  the  surfaces of other 
cells.  Although  this response depends  on the TCR,  other 
cell  surface  molecules  contribute  to  T  cell  activation  by 
promoting  adhesion  to  the  APC  and  by providing  bio- 
chemical signals.  CD2,  a  55-kD  cell  surface glycoprotein 
expressed by T  lymphocytes and NK cells, subserves adhe- 
sion functions by binding CD48,  CD58,  and CD59  (1-3). 
It is likely that CD2 also has a role in generating transmem- 
brahe signals  during the activation of T  cells  and NK cells 
(4, 5).  Perturbation of CD2 can trigger the cytolytic activ- 
ity of NK cells and can provide a potent stimulus for T  cell 
activation,  inducing  proliferative responses  comparable to 
those  elicited  by either mitogenic lectins  or mAbs to  the 
TC1K (4,  5).  In several experimental systems, CD2-medi- 
ated  signaling  augments  antigen-induced  activation  of T 
cells (6, 7). Moreover, administration ofnondepleting CD2 
mAbs to mice induces T  cell unresponsiveness,  indicating 
that  CD2  either has a  critical  role  in  T  cell activation in 
vivo or can deliver signals  leading to unresponsiveness (8). 
CD2-deficient mice, however, do not manifest an obvious 
phenotype, suggesting that, ifCD2 does have a critical role 
in physiological T  cell activation, other molecules can as- 
sume that role when T  lymphocytes develop in the absence 
of CD2  (9).  Alternatively,  the  functional  deficit  resulting 
from the abscence of CD2 may be subtle. Of interest in this 
regard, recent data suggest that CD2 plays a unique role in 
the reversal ofT cell anergy in vitro (10). 
The mechanism by which CD2 couples to signal trans- 
duction pathways is uncertain. When T  cells are lysed with 
digitonin  or  Brij,  CD2  coimmunoprecipitates  with  the 
TCR  (11-14).  Therefore,  like  CD4  and  CD8,  CD2  ap- 
pears to be in close physical proximity with the TCR  (11- 
14).  Indeed,  CD2-mediated  activation requires  coexpres- 
sion of TCR or of receptor complexes, such as CD16, that 
contain the TCk-{  chain or the closely related Fce recep- 
tor ~ chain (15,  16). Thus, agonist mAbs to CD2 fail to ac- 
tivate T  cell lines that express abundant CD2 but that lack 
TCR  (15).  As is the case with the TCP.., appropriate stim- 
ulation  of  CD2  induces  tyrosine  phosphorylations  and 
polyphosphoinositide turnover (17-20). These CD2-induced 
signaling events depend on the cytoplasmic domain of CD2, 
which  is relatively large  (116  amino acids),  is highly con- 
served between human,  rat, and mouse, and lacks intrinsic 
kinase activity (21-24). 
The remarkable capacity of CD2 to activate T  ceils and 
NK cells raises the possibility that, like the TCR, CD4, and 
CD8, CD2 interacts with cytoplasmic protein tyrosine ki- 
nases (PTK). 1 Several observations support this possibility. 
Perturbation of CD2 induces protein tyrosine phosphoryla- 
1Abbreviations used in this paper: F.L., full-length; GST, glutathione-S-trans- 
ferase; PTK, protein tyrosine kinases; S/9, Spodopterafrugiperda. 
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transmembrane tyrosine phosphatase that regulates the ac- 
tivities of Src-like PTK (20, 25). Stimulation of CD2 on T 
cells leads to an increase in the specific activity of p56  kk, a 
lymphoid-specific Src-like PTK (26). We and others have 
found  that  p561Ck as  well  as  p59  fin  coimmunoprecipitate 
with CD2 from detergent lysates of rat T  lymphocytes and 
NK cells,  raising the possibility that CD2 associates directly 
with these Src-like PTK (12,  13,  27).  Herein we examine 
the mechanism by which CD2 associates with p56  kk. 
Materials  and Methods 
Cell Lines,  Cell Culture, mAbs,  and  Other Reagents.  COS 6M 
cells were grown in DME with 10% FCS.  Spodopterafrugiperda 
(sfg) cells were  grown in complete  Grace's  medium. Anti-rat 
CD2 mAbs OX-34, OX-54, and OX-55 were the kind gift of A. 
Williams (Oxford University, Oxford, UK). 
Generation of  Fusion Proteins and Anti-GST Antiserum.  The  don- 
ing of Wild Type p56 kk into the baculovims shuttle vector pBMS-1 
has  been previously reported  (28). Domains encompassing the 
unique regions  SH2  and SH3 were cloned in frame  with GST 
into the pGEX-2T vector (Pharmacia, Uppsala, Sweden) by PCR. 
The  unique sequence  fusion  encompassed  amino  acids 8-65, 
whereas the SH3 and SH2 fusions encompassed amino acids 66-113 
and 114-235, respectively,  of the Wild Type gene. The unique 
sequence and  GST  alone were  produced with  isopropyl-[3-D- 
thiogalactopyranoside  according  to  the  manufacturer's instruc- 
tions (Pharmacia  LKB Biotechnology Inc., Piscataway,  NJ) and 
used for injections in New Zealand white rabbits for polyclonal 
antisera production. HIS-T7 epitope-tagged fusion proteins were 
made by cloning the appropriate  portions of the rat  CD2 cyto- 
plasmic domain in frame into the pet-28 vector (Novagen, Inc., 
Madison, WI) by PCR.  Protein production was  induced with 
IPTG and purified according to the manufacturer's instructions. 
Generation ofCD2Mutants.  The  CD2  truncation  mutants 
were  generated by PCP- using the  rat  cDNA provided by A. 
Williams.  The 5'  oligonucleotide located  upstream of the  CD2 
start site contained an EcoRI site and was used for all PCR. Its se- 
quence is 5'-TATATATATAGAATTCCACTGGGA  AAAGAA- 
TGTAAAGATGAGATG-3'.  To generate the truncation mutants, 
we  synthesized  antisense  oligonucleotides  containing  a  stop 
codon after  the  appropriate  amino acid  followed by restriction 
sites. The sequences  for CY6,  CY40, CY78,  CY85,  and CY105 
are 5'-TATTTAAGCTTGCGGCCGCTAGTTCCGTTTTTT- 
CCTCTTCA-3', 5'-TATATATATGAATTCGTCGACCTA- 
TGATGCTGGTGAGGCCTGGGTTGAGTGTGGCTTGGG- 
3', 5'-TATATAATAGTCGACGCGGCCGCCTATCTCTTC- 
TTCGGCTGGTGCTCACG-3', 5'-TATAATATAGTCGAC- 
GCGGCCGCTACTGTGTGCCTGATGGAGGAGGTCTC-3', 
and 5'-TATATATATGAATTCGTCGACCTAACAGGGAGG- 
CTTTGGCTGAACTCGGGGTCTGGGCAAAGG-3',  respec- 
tively. The PCR products were cloned into pSM for expression 
in COS cells and pVL1393  for recombination with BaculoGold 
DNA and expression in Sf9 cells (PharMingen, San Diego, CA). 
The internal deletion designated  CY49.69  (lacking amino acids 
49-69 of the cytoplasmic tail of rat CD2) was generated by over- 
lap PCR as described  (29). 5' and 3' overlapping PCR fragments 
were  generated for the internal deletion. Oligonuceotides used 
for the PCR reactions were as follows: 5' fragment of CY49.69, 
5'-TATATATATAGAATTCCACTGGGAAAAGAATGTAAA- 
GATGAGATG-3' and  5'-CTTCGGCTGGTGCTCACGGTT- 
AGCTTGGGAAGCCACTGGATT-3';  and the 3' fragment of 
CY49.69, 5'-AATCCAGTGGCTTCCCAAGCTAACCGTGAG- 
CACCAGCCGAAG-3' and 5'-TATAAAGTCGACGCGGCC- 
GCTTAATTAGGGGGTGGCAACGAAAC-3'. The  internal 
deletion designated CY7.4l (lacking amino acids 7-41 of the cyto- 
plasmic tail of rat CD2) was also generated by overlap PCR using 
the following primers: 5' fragment of CY7.41,  5'-TATATAGAA- 
TTCCACTGGGAAAAGAATGTAAAGATGAGATG-3'  and 5'- 
GTGCTCACGGTTGCCAGGTGTCTGGAGATG-3';  and the 
3' fragment of CY7.4l, 5'-CAGACACCTGGCAACCGTGAG- 
CACCAGCCG-3' and 5'-TATAAAGTCGACGCGGCCGCT- 
TAATTAGGGGGTGGCAACGAAAC-3'.  The DNA sequence 
of the cytoplasmic domain of each mutant was verified. 
Expression of Full-Length  and Mutant  CD2  and p5~  "k in  COS 
Cells and Sf9 Cells.  The various CD2 constructs and p56  lck were 
expressed in COS cells by transient transfection using DEAE dex- 
tran  (Sigma  Chemical Co.,  St.  Louis,  MO)  according to  pub- 
lished  methods  (30). To express the  constructs  in Sf9  cells, we 
transfected the various constructs into Sf9 cells in the presence  of 
BaculoGold DNA (PharMingen) according to the manufacturer's 
instructions, harvested,  and amplified the recombinant baculovi- 
rus.  The virus was then used  for large-scale preparations  of re- 
combinant protein. 
Immunoprecipitations,  In  Vitro Kinase  Assays,  and  Immunoblot- 
ring.  Anti-CD2  immunoprecipitations were  performed  using 
either mAb OX-34  (mouse  IgG2b)  coupled to  Pansorbin cells 
(Calbiochem Corp., LaJolla,  CA), or mAb OX-55 (mouse IgG1) 
coupled either to Pansorbin cells coated  with rabbit anti-mouse 
Ig antiserum (Cappel  Laboratories,  Malverne, PA) or to Sepha- 
rose-coupled goat  anti-mouse Ig (Cappel  Laboratories).  In vitro 
kinase assays were performed as described (27). Anti-GST immu- 
noblots were performed by blocking the gel transferred to Immo- 
bilon-P (Millipore  Corp., Bedford,  MA) in 20 mM Tris,  pH 8, 
150 mM NaC1, 0.05% Tween 20  (TBST)  with 3% nonfat dried 
milk for 30 min followed by incubation with anti-GST antiserum 
(1:500 in TBST with 3% milk) for 2 h at room temperature.  The 
blots were washed three times for 5 rain in TBST and incubated 
with 12SI-labeled  protein A (Amersham Corp., Arlington Heights, 
IL) at 0.5 mCi/rnl in TBST with 3% milk for  1 h at room tem- 
perature.  The blots were washed three times for 5 rain in TBST, 
dried, and evaluated by autoradiography.  Anti-rat CD2 immuno- 
blots were performed as above using mAb OX-34 at 0.1  Izg/ml 
in TBST with  3%  milk,  and anti-T7 immunoblots were  per- 
formed  using anti-T7 mAb  (Novagen,  Inc.)  according to  the 
manufacturer's instructions. 
Peptide Generation.  The peptides  used  in these  studies  were 
purchased  from either Chiron Mimotopes Peptide Systems (San 
Diego,  CA)  or Research  Genetics  (Huntsville, AL), analyzed by 
mass spectometery or HPLC, and were I>70% pure. The sequences 
of each peptide are as follows: peptide 1, ASQAPPPPGHH; pep- 
tide 2, PGHRPLPPSHR; peptide 3, PKKRPPPSGTQ; peptide 
4, GQKGPPLPIq.PRV; and peptide 5, RVQPKPPCGSG. (Pep- 
tide 4 is a 12-met; a glycine was added to the NH  2 terminus to 
prevent cyclization  of the NH2-terminal glutamine.) Equivalent 
molar quantities of the peptides were conjugated to activated CH 
Sepharose 4B (Pharmacia LKB Biotechnology Inc.) per the man- 
ufacturer's  instructions and  were  used  to  precipitate  purified 
GST/p561ok. 
Determination of Ca  2§  Fluorescence and IL-2 Production.  Jurkat 
cells were loaded with the Ca2+-sensitive fluor and lndo-1, and 
calcium fluorescence  was monitored as previously described  (31). 
To determine IL-2 production, we  cultured Jurkat  cells at  1()  ~ 
cells/ml in 96-well plates and stimulated the cells for 18 h with 
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coprecipitates with  CD2  from rat  T 
cells. Freshly  isolated  rat splenic  T cells 
were lysed in a buffer containing 1% 
NP-40, and 500 lig of the precleared 
lysate was  subjected to  immunopre- 
cipitation  with antibodies directed 
against either CD2  (OX-34), CD4 
(W3-25), or  CD8  (OX-8)  as  indi- 
cated. The  immune complexes were 
washed and incubated in a kinase reac- 
tion  buffer containing  10  p,  Ci  of 
[~/-32p]ATP  as  previously described 
(27). Phosphoproteins were separated 
by SDS-PAGE on an 8% gel, treated 
with 1 M KOH at 55~  for 1 h, and 
evaluated by autoradiography. Molec- 
ular masses and the location of p56  kk 
are indicated  on the left. 
media, PMA alone (10 ng/ml), the combination of OX-54 (20 
I~g/ml),  OX-55  (20  Ixg/ml)  and PMA,  or the  combination of 
C305  (1:500  dilution from ascites) and PMA. Culture supema- 
tants were assayed for IL-2 using a human IL-2 cytoscreen immu- 
noassay kit (Biosource International, Camarillo,  CA) according to 
the manufacturer's instructions. 
Results 
CD2 and p561ok Associate  in Rat  T  Cells,  and  This Associa- 
tion Can Be Reproduced  in  COS  Cells.  As  is  the  case  with 
CD4  and  CD8,  immunoprecipitates  of  CD2  from  1% 
NP-40 lysates of splenic T  cells contain a protein kinase ac- 
tivity detected  by in vitro kinase assays  (Fig.  1).  We  and 
others have identified p56  kk as one of the PTKs present in 
these CD2 immunoprecipitates (12,  13, 27). To determine 
whether  CD2  and p56  lck  can associate  in a  nonlymphoid 
cell line,  we  transfected  COS  cells  (a  fibroblast line that 
does not express p56  kk)  with cDNAs encoding p56  lck and 
rat CD2.  After 72 h,  the cells were solubilized in a buffer 
containing 1%  NP-40,  and  the  resulting lysate  was  sub- 
jected  to  immunoprecipitation with  antibodies  directed 
against CD2 and p56  kk (Fig. 2 A). An in vitro kinase assay 
performed  on  the  CD2  immunoprecipitate  generated 
prominent phosphorylated bands that comigrated with au- 
tophosphorylated p56  lck. The presence of kinase activity in 
the  CD2  immunoprecipitate  required  transfection  with 
both the CD2 and p56  lck cDNAs. There was no kinase ac- 
tivity in CD2  immunoprecipitates from  COS  cells  trans- 
fected with p56  lck alone, indicating that the CD2 mAb does 
not cross-react with a PTK. Similarly, in vitro kinase reac- 
tions on CD2  immunoprecipitates from  COS  cells trans- 
fected with CD2 alone failed to reveal bands corresponding 
to Src-family members. Taken together, these results indi- 
cate that rat CD2 and p56  Ick associate when coexpressed in 
COS cells. Comparable results were obtained when human 
CD2  was  coexpressed with p56  lck  in COS  ceils  (data  not 
shown). CD2, therefore, does not require the expression of 
any other lymphoid specific molecules to associate with p56  lck. 
CD2 also binds p56  kk when the latter is in the form of a 
purified GST fusion protein. After incubating GST/p56  kk 
with lysate from CD2-expressing COS cells,  we immuno- 
precipitated  CD2  and then analyzed the  immunoprecipi- 
tate  for  the  presence  of GST/p56  lck  by  immunoblotting 
with an antiserum to  GST. As shown in Fig.  2  B,  GST/ 
p56  l~k  coprecipitates with  CD2.  This  association requires 
the presence of the CD2 cytoplasmic domain, as evidenced 
by the failure to detect GST/p56  kk in immunoprecipitates 
of a truncation mutant ofCD2 (CY6) that lacks all but the 
first six amino acids of the cytoplasmic domain of CD2. 
The  SH3  Domain  of p56  l"k Mediates Association  with  CD2. 
To determine the region of p561ok that binds to  CD2, we 
constructed GST fusion proteins containing the following 
domains of p56kk:  the  NH2-terminal unique region,  the 
SH3 domain, and the SH2 domain (Fig. 3). In these exper- 
iments, we used Sf9 cells (a blowfly salivary gland cell line) 
that expressed CD2 after gene transfer. Each of the fusion 
proteins  was  incubated  with  equal  aliquots  of  CD2- 
expressing Sf9 lysate, and then immunoprecipitations with 
anti-CD2 mAb were  performed.  The  immunoprecipitate 
was  analyzed  by  inmmnoblotting with  anti-GST.  The 
GST/SH3 domain fusion protein coprecipitated with CD2, 
but GST alone, the GST/unique region fusion protein, and 
the  GST/SH2 domain fusion protein did not  (Fig.  4  A). 
Next we determined if the GST/SH3 domain fusion pro- 
tein  could  competitively inhibit the  association  of CD2 
with  full-length GST/p56  kk  (we  used  the  fusion protein 
rather than p56  Ick because the fusion protein could be easily 
purified, permitting better control of its concentration). In 
each of several experiments, the GST/SH3 domain fusion 
protein, but not GST/unique region or  GST alone  (data 
not shown), inhibited the binding of CD2  to  GST/p561ok 
(Fig. 4 B). As was the case with GST/p56  lck, the GST/SH3 
domain  fusion  protein  associated  with  full-length  (F.L.) 
Figure 2.  The association of CD2 with p56  kk can be re- 
produced in nonlymphoid cells and requires the cytoplasmic 
domain of CD2. (A)  p56  lck  coprecipitates with rat  CD2 
when expressed in COS ceils. COS cells were plated onto 
100-cm  2 dishes and transfected with 5 ~g of plasrmd DNA 
encoding the molecules  indicated (Tx). After 72 h, the cells 
were lysed in buffers containing 1% NP-40, and the pre- 
cleared lysates were subjected to immunoprecipitation  with 
the indicated antibodies  (IP). The immune complexes were washed and incubated in a kinase reaction buffer containing 20 p.Ci of ['y-32p]ATP.  Phos- 
phoproteins were separated by SDS-PAGE on an 8% gel and evaluated  by autoradiography. OX-55 (anti-rat CD2 mAb), OX-8 (isotype-matched  con- 
trol mAb recognizing  rat CD8), and crick (rabbit  antiserum  recognizing  p56  kk) were used in the immunoprecipitations.  (B) GST/p56  lck fusion  protein as- 
sociates with full-length  CD2 (F.L.) but not a tailless CD2 construct (CY6) produced in COS cells. 3 p,g of purified GST/p56  I~k was added to a COS cell 
lysate containing either F.L. CD2 or a truncation mutant lacking a cytoplasmic  domain (CY6). CD2 was immunoprecipated  from the lysates, and the 
CD2 immunoprecipitates  were then analyzed  by irrmmnoblotting  with anti-GST antiserum. 
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Similarly, immobilized GST/SH3 domain fusion protein pre- 
cipitated F.L. CD2, but not CY6, from SJ9 lysates (Fig. 4  D). 
The  Cytoplasmic  Domain  of CD2  Directly Associates with 
p56  tck.  To  determine if p56  lck binds directly to  the  cyto- 
plasmic domain of CD2,  we  constructed two  nickel histi- 
dine  T7  epitope-tagged  fusion proteins:  one  of the  full- 
length cytoplasmic domain ofCD2  (T7-CY)  and one con- 
taining the first 40  amino acids of the cytoplasmic domain 
of CD2  (T7-40).  The fusion proteins were purified to ho- 
mogeneity,  immobilized onto  Sepharose  with  an  anti-T7 
mAb,  and  used  to  affinity precipitate  purified  GST/SH3 
fusion protein.  The  GST/SH3  fusion coprecipitated  with 
the full-length cytoplasmic domain but not with the fusion 
protein containing the first 40 amino acids (Fig. 5 A). Sim- 
ilarly, immobilized GST/p56 kk fusion protein precipitated 
T7-CY,  but not T7-40  (Fig.  5  B).  These  studies  indicate 
p56  lck binds directly to the cytoplasmic domain of rat CD2 
and that the first 40 amino acids of the cytoplasmic domain 
of CD2 are not sufficient for this binding. 
Identification of the  Minimal  Cytoplasmic  Domain  of CD2 
Required for Binding top56  Ick.  To  determine  the  minimal 
Figure  3.  Schematic  representation  of 
p56  l& and the  GST/p56  kk fusion proteins. 
The structure of p56  lck can be divided into 
an NHg-terminal  myristylation site (MYR), 
a unique region, SH3 and SH2 domains, a 
catalytic  domain,  and  a  COOH-terminal 
regulatory region (REG). 
cytoplasmic domain of CD2  needed for binding to  p56  kk, 
we  constructed a  series  of CD2  truncations in addition to 
CY6.  Mutants containing 40,  78,  85,  and  105  of the  116 
amino acids in the cytoplasmic tail of rat CD2 were gener- 
ated  by  PCI<  and were  designated  CY40,  CY78,  CY85, 
and CY105,  respectively (Fig. 6). 
We  expressed  F.L.  CD2  and each of the mutants in Sf9 
cells  and  then  determined  their  ability  to  associate  with 
p56  lck.  Lysates  from  the  CD2-expressing  Sf9  cells  were 
combined  either  with  wild-type  p56  lck  produced  in  Sf9 
cells (Fig. 7 A) or with purified GST/p561ok (Fig. 7  B). F.L. 
CD2 and the CD2 mutants were immunoprecipitated, and 
the  immunoprecipitates  were  analyzed  either  by  in  vitro 
kinase reaction (Fig. 7 A) or by immunoblotting with anti- 
GST antiserum (Fig. 7/3).  In both experiments, equivalent 
activities or amounts of p561ok coprecipitated with F.L. and 
CY105  (Fig. 7).  As the cytoplasmic tail of CD2 was short- 
ened from  105  amino acids to  85 amino acids,  there was a 
decrease in the associated p56  lck to r176  of that seen with 
F.L.  (determined by densitometry of Fig.  7  /3).  There  was 
no  change  in  the  associated  p56  lck  as  the  cytoplasmic  tail 
was shortened from 85 to 78 amino acids (Fig. 7  B). As the 
Figure 4.  The association between CD2 and p56  lck requires the cytoplasmic domain of CD2 and the SH3 domain of p56  kk. (a) After the addition of 
1.5 Ixg of GST, GST/p56  lck unique region, GST/p56  lck SH2 domain, or GST/p56  lCk SH3 domain to S  f9 lysate containing  F.L. CD2, CD2 was immuno- 
precipitated, and the immunoprecipitate was analyzed for associated fusion protein by anti-GST immunoblotting. (b) 5 Ixg of GST/p56  kk unique region 
or GST/p56  lck SH3 domain (final concentration ~333 nM each) was incubated in 500 txl Sf9 lysate containing F.L. CD2 for 30 rain before the addition 
of 3 btg GST/p56  Ick (66 nM) The lysates were precleared and then immunoprecipitated  with mAb directed against rat CD2 and analyzed for associated 
fusion protein by inmmnoblotting  with anti-GST. Binding of the GST/p561ck fusion protein (31 kD) to CD2 is not detected because of its lower mo- 
lecular mass. (c) 1.5 txg of GST/p56  kk SH3 domain was added to Sf9 lysate containing either F.L. CD2 or CY6, which was then immunoprecipitated 
with mAb directed against rat CD2 and analyzed for associated fusion protein by immunoblotting. (d) To equimolar amounts of F.L. CD2 and CY6, 
sepharose bound GST/p56  kk SH3 was added and incubated for 1.5 h. The affinity precipitations were separated by SDS-PAGE and immunoblotted  with 
anti-rat CD2 mAb. Molecular masses are indicated on the left. Each figure is representative of at least three independent experiments. 
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CY (lane 1) and T7-40 (lane 2) purified fusion proteins were immobilized 
onto anti-T7 mAb coupled to Sepharose bound rabbit anti-mouse antise- 
rum and used to affinity precipitate 0.5 Ixg of GST/SH3 fusion protein in 
1% NP-40 lysis buffer. The precipitates were washed three times in lysis 
buffer, eluted with Laemmli sample buffer, separated by SDS-PAGE, and 
immunoblotted with anti-GST antiserum.  The  presence  of equimolar 
amounts of T7-CY and T7-40 was confirmed by immunoblotting  with 
anti-T7 mAb (data not shown). (b) To equimolar amounts of T7-CY and 
T7-40 fusion protein,  Sepharose bound GST/p56  kk SH3 was added and 
incubated for 1.5 h. The GST fusion protein was eluted in 10 mM glu- 
tathione, and the affinity precipitations were separated by SDS-PAGE and 
immunoblotted  with anti-T7 mAb. Molecular masses are indicated on the 
left. Each figure is representative of  at least three independent experiments. 
Figure  7.  Association of p56  lck with F.L. rat CD2 and truncation and 
internal deletion mutants of rat CD2. Lysates of Sf9 cells expressing F.L. 
or the indicated CD2 mutants were mixed with either p56  ]~k produced in 
Sf9 cells (a) or purified GST/p56  kk fusion protein (b and c). The lysates 
were precleared, immunoprecipitated  with anti-rat CD2, and subjected 
to in vitro kinase reactions (a) or immunoblotted with anti-GST antise- 
mm (b and c). Expression of the CD2 constructs was analyzed by flow cy- 
tometry,  and anti-CD2 blotting of the lower  half of the immunoblots 
confirmed the presence of equimohr concentrations of each of the con- 
structs (data not shown). 
cytoplasmic domain was  truncated to  40  amino acids,  vir- 
tuaUy all p561Ck binding was eliminated (Fig. 7). Although a 
small amount of GST/p56 kk was seen in the CY40 immu- 
noprecipitate, this was not a  consistent finding in other ex- 
periments.  Immunoblots of these  samples  with  a  mAb  to 
extracellular CD2  revealed that there was severalfold more 
CY40 than F.L.  (data not shown). When  corrected for the 
amount of CD2  in the  immunoprecipitates in Fig.  7,  the 
GST/p56 kk  in CY40  immunoprecipitates represents '-~ 
of that in F.L. CD2 immunoprecipitates. 
The  data in Fig.  7  are  consistent with two  possibilities. 
First, there may be two binding sites for p56  kk in CD2: one 
between  amino  acids  40  and  78  and  another  between 
amino  acids  85  and  105.  Alternatively,  there  may  be  a 
proximal  binding site  that  is  secondarily  affected  by  the 
truncation such that its ability to bind is impaired. To dis- 
tinguish between these  possibilities, we  generated  two  in- 
ternal  deletion  mutants  of CD2:  one lacking amino acids 
49-69 and the other lacking amino acids 7-41  of the cyto- 
plasmic domain (designated CY49.69 and CY7.41,  respec- 
tively; Fig. 6). We expressed F.L. CD2  and each of the in- 
ternal  deletion  mutants  in  SJ9  cells  and  determined  their 
ability to  associate with purified GST/p56  kk.  Immunopre- 
cipitates of F.L. CD2  and the CD2  mutants were  analyzed 
by immunoblotting with anti-GST antiserum (Fig. 7  C). In 
each  of several  experiments,  CY7.41  consistently bound 
more GST/p56 lck than F.L. indicating that the membrane- 
proximal portion of the cytoplasmic domain of CD2 is not 
required  for  binding  to  p56  kk.  CY49.69  bound  GST/ 
p56  kk, but not as well as F.L., CD2, consistent with a possi- 
ble  p56  Ick  binding site  between  amino  acids  40  and  78. 
Taken together with the truncation studies, these data indi- 
cate that CD2 has two discrete regions that bind p56kk: one 
between  amino  acids  40  and  78  and  the  other  between 
amino acids 85 and 105 of the cytoplasmic tail of rat CD2. 
Proline-rich Sequences  fiom the Cytoplasmk  Domain  of CD2 
Bind p56  tck.  Studies  by  several  investigators  indicate  that 
the binding sites for SH3  domains are rich in proline resi- 
dues (32-35). The cytoplasmic tail of CD2 has several pro- 
line-rich domains.  Two  of these  (amino  acids  92-95  and 
F.L 
CYIOS 
CY~ 
CY78 
CY40 
CY6 
CY49.69 
CY7.41 
Figure 6. 
AMINO ACID SEQUENCE OF THE CYTOPLASMIC DOMAIN OF F.L. CD2 AND EACH OF THE CD2 MUTATIONS 
KRKIGRNRRRKOb2h7  ~KA~STVERGPKPB~TQA,~,PASQNPVASQA~I~HI-ILQTIE~IRNREHQ~Q~K~VO~DV$~N 
KRK]C.RNRRRKGI~/~I  ~nIKASRMSTVI~STQASAPASQNPVASQAPPPPGHI~HRPLP~QpKK]p..pPPSGTQ~KG~RVQ~ 
KRKKRNRRRKGg'b-'T  b-'mC,  A~STVERGPKIR-ISTQASAPASQNIWASQAPPPPGHHI.QTI~HRPLppsiRRNRI~QPKKRPP~ 
KRKKRNRRRKG~-'T  ~CA.SRMSTVI~GPKPHSTQASAPASQNI~VASQAPPPPGHHI~TPGHRPLP~QPKKR 
KRKKRNRRRKGb-'I~  I~IKASRMSTV][~GPKPHSTQASAPAS 
KRKKR.,N'RRRKG~  ~'T  ~IKASRM STVERGPKPHSTQA  SAPASQNPVASQA  ~QPKKRPPPSGTQVHQQKGPPLPRPRVQPKPPC~SGDVSLPPPN 
KRKKRN  NPVASQAPPPPGHHLQTPG~SHRNREHQPKKRPPPSGTQVHQQKGPPLPRPRVQPKPPCGSGDVS~PpN 
Amino acid sequence of the cytoplasmic domain of F.L. rat CD2 and the various CD2 mutants. Proline-rich regions are underlined in the F.L. 
173  Bell et al. 101-104;  Fig.  6)  lie  in  the putative  binding regions  indi- 
cated above between  amino acids  85  and  105.  Two other 
proline-rich regions lie between amino acids 49 and 66, the 
putative binding region deleted in the CY49.69 mutant. A 
fifth proline-rich sequence (amino acids 79-81) lies  in a re- 
gion whose truncation had no detectable effect on the abil- 
ity of CD2 to associate with p561ok. 
To  investigate  the  possibility  that  one  or  more  of the 
CD2 proline-rich sequences could bind p56  lck, we synthe- 
sized  11-mer  peptides  corresponding  to  the  five  proline 
rich regions between amino acids 49 and 105. The peptides 
were coupled to activated Sepharose and then incubated in 
lysis  buffer with  full-length  GST/p56  kk.  Eluates  from the 
immobilized  peptides  were  assayed  for  the  presence  of 
GST/p56  l&  by  anti-GST  immunoblotting.  Two  peptides 
(designated 2 and 4) consistently bound GST/p56  kk (Fig. 8 
A).  Peptide  2  corresponds  to amino  acids  59-69  and thus 
lies  within  the  putative  binding site  between  amino  acids 
40  and 78.  Peptide  4  represents  amino  acids  89-99  and is 
within  the  putative  binding  site  between  amino  acids  85 
and  105.  Peptide  1, which also lies within  the amino  acid 
40-79  site,  bound GST/p56  l~k poorly (relative  to peptides 
2 and 4) in two experiments  (Fig. 8 A) or not at all in eight 
experiments  (data not shown). Peptide 3  (which resides be- 
tween amino acids 75 and 85) and peptide 5  (which resides 
between  amino  acids  98  and  108)  failed  to  bind  in  every 
experiment (Fig. 8 A). There also was no binding to a con- 
trol peptide corresponding to a CD2 cytoplasmic sequence 
that was not rich in prolines (data not shown). 
Because peptide 2 bound GST/p56  lck best, we determined 
the effect on binding of truncating this peptide. The following 
peptides  were  synthesized,  immobilized  on Sepharose,  and 
assayed for their ability to bind GST/p561ck:  HI<PLPPSHI(, 
PLPPSHI(  and  HI<PLPPS.  Only  HI(PLPPSHI(  bound 
GST/p56 lck (Fig. 8 B). This peptide differed from peptide 2 
by the deletion of PG on the NH2 terminus.  The removal 
of the  HI< from either  the  NH2 terminus  or the  COOH 
terminus  resulted  in loss  of binding  (Fig.  8  /3), suggesting 
either  that  the  flanking basic  amino  acids  are  required  for 
binding of this peptide to the SH3 domain of p561ok or that 
the  peptide  length  must  exceed  seven  residues.  Although 
our studies  do  not  distinguish  between  these  possibilities, 
the  sequences  of the  first  and  second proline-rich  regions 
are quite similar, the major difference being that the second 
has basic amino acids at both flanks of the prolines, whereas 
the  first  has  basic  residues  at  the  carboxy terminus  only. 
The  absence  of NH2-terminal  basic  residues  may  explain 
the  decreased  ability  of the  peptide  derived  from the  first 
proline-rich region (peptide  1) to bind GST/p56  lck. 
The First Two Proline-rich Regions in the Cytoplasmic Tail of 
CD2  Are  Not  Required for  Coupling  to  Signaling  Pathways. 
Previous studies  examining the structural  requirements  for 
signal transduction by human  CD2  indicated  that the first 
two proline-rich regions in the cytoplasmic domain of hu- 
man  CD2  were  required  for signal  transduction  by  CD2 
(21,  36, 37).  Chang et al.  (21)  demonstrated that a trunca- 
tion mutant retaining 77 amino acids, but not one retaining 
43 amino acids, of the cytoplasmic domain of human CD2 
could couple to a rise in free intracellular calcium ([Ca>]i) 
and IL-2 production,  suggesting that an essential  sequence 
for human CD2 signal transduction lies between amino ac- 
ids 43 and 77. Point mutations on either side of the second 
proline-rich  domain did not affect IL-2 production,  but a 
substitution  of DE  for the  HI< after  the  first  proline-rich 
region abrogated signaling, consistent with a key role of the 
first  proline-rich  region  in  CD2  signal  transduction  (37). 
This  finding  could  not  be  corroborated  by  Hahn  and 
Bierer  (36), who found that the same HI( to DE substitu- 
tion  failed  to  have  an  effect  on  CD2  signaling.  They did 
note that deletion of either the first or second proline-rich 
region resulted in a reduction of CD2-mediated IL-2 pro- 
duction,  and elimination  of both regions completely abro- 
gated  CD2  signaling  (36).  Therefore,  although  the  studies 
differed on the  relative  importance  of the  first and second 
proline-rich regions, both studies clearly defined this region 
as essential for CD2-mediated signaling. 
Our CY78  mutant,  which retains  the first two proline- 
rich regions in the  cytoplasmic domain  of CD2,  can bind 
p56  lck in vitro and,  thus,  is consistent with  the notion that 
the binding of p56  lck by CD2 is important  in  CD2-medi- 
ated  signaling.  On  the  other  hand,  based  on  the  earlier 
functional studies,  our CY49.69 would not be expected to 
couple  to  signaling pathways  even  though we find that  it 
binds  p56  lck  in  vitro  (36,  37).  Therefore,  we  investigated 
the  possibility  that  CY49.69  could  couple  to  signaling 
pathways  in  T  cells.  To  this  end,  we  expressed  F.L.  rat 
Figure  8.  Binding of  GST/ 
p56  kk  by  proline-rich peptides. 
(a)  Proline-rich peptides in  the 
cytoplasmic domain of CD2 can 
bind  p56  lck.  l l-mer  peptides 
corresponding  to  five proline- 
rich regions (1-5) in  the  cyto- 
plasmic domain of CD2  were 
synthesized (peptide 4  is  a  12- 
mer; a glycine was added to the 
NH2  terminus  to  prevent cy- 
clization  of  the  NH2-terminal 
glutamine). The locations and sequences of  the peptides are indicated in the diagram. The peptides were coupled to Sepharose and used to precipitate pu- 
dried GST/p56  lck. (b) The effect of truncations on the ability ofpeptide 2 to bind p56  lck. Peptides indicated above the lanes in Fig. 8 b were synthesized, 
conjugated to Sepharose, incubated with equivalent concentrations of  purified GST/p56  l'k, and immunoblotted with anti-GST antiserum. 
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Figure 9.  Anti-CD2  mAb  (OX-54  and 
OX-55)  trigger  an  increase in  [Ca2+]i in 
F.L. CD2 and CY49.69 when expressed in 
Jurkat.  The  calcium-sensitive fluorescence 
of a suspension of Jurkat  cells expressing 
F.L. rat CD2 and CY49.69 was monitored 
over time. At the indicated times, the cells 
were stimulated with 5 Dg of OX-54 and 5 
b~g of OX-55 for every 106 cells. Values for 
[Ca2+]i (nM) were  calculated as described 
and are indicated on the righthand side of 
the figure (31). These data are representative 
of at least three separate experiments. 
CD2  and  the  CY49.69  mutant  in the human  T  cell line, 
Jurkat, and assessed the ability of each to couple to a rise in 
[Ca2+]i and to produce IL-2 after CD2 stimulation. 
As previously described, F.L. CD2 can stimulate a rise in 
[Ca2+]i when  activated with  a  pair of anti-rat CD2  mAb 
(OX-54 and OX-55;  Fig. 9).  Similarly, the CY49.69  con- 
struct stimulated a  rise in  [Ca2+]i  comparable to  that seen 
with  F.L.  CD2  when  activated with  OX-54  and  OX-55 
(Fig. 9). To determine whether these constructs are capable 
of producing IL-2 in response to anti-CD2 stimulation, we 
stimulated F.L. CD2 Jurkat and CY49.69 with PMA alone, 
the  combination  of OX-54,  OX-55,  and  PMA,  or  the 
combination of C305  (anti-TCR.) and PMA. As previously 
demonstrated,  stimulation of F.L. rat  CD2  results in IL-2 
production comparable to that seen after TCP, stimulation 
(Table 1). CY49.69 also produced IL-2 in response to CD2 
stimulation, and the amount of IL-2 produced was compa- 
rable to that elicited by TCR. stimulation (Table 1). These 
data demonstrate that the first two  proline-rich regions in 
the  cytoplasmic tail of CD2  are not  required for CD2  to 
transduce signals. 
Discussion 
In  this  report  we  have  examined  the  mechanism  by 
which  CD2  and p56  kk associate. The interaction between 
these does not require the coexpression of other leukocyte- 
specific molecules, as evidenced by the ability of CD2  and 
p56  kk to associate in COS cells and Sf9 cells. Therefore, al- 
though  CD2  coprecipitates  with  a  number  of lineage- 
restricted molecules, including the TCR., CD4, CD45, and 
CD53,  none of these need be present for CD2  to associate 
with p56  kk (11,  t2).  The association requires the cytoplas- 
mic domain of CD2,  to which the SH3  domain of p56  lck 
binds.  Truncation  mutants  of  CD2  reveal  two  regions 
whose deletion leads to a substantial decrease in the amount 
of p56  lck that coprecipitates with CD2. When the cytoplas- 
mic domain is shortened from 105 to 85 amino acids, there 
is a 70% decrease in the amount of p56  kk binding, relative 
to full length CD2.  As the cytoplasmic tail of CD2  is fur- 
ther  shortened  from  78  to  40  amino  acids,  virtually  all 
binding to  p56  lck is lost. Each  of these  regions  contains a 
proline-rich sequence that, in the form of an immobilized, 
synthetic peptide, binds p56  kk. Thus proline-rich sequences, 
which are a distinctive feature of the CD2  cytoplasmic do- 
main, allow this transmembrane receptor to couple to p56  lck 
by binding its SH3 domains. 
SH3 domains, which are found primarily in enzymes and 
other  molecules  involved  in  signal  transduction,  mediate 
protein-protein interactions (38).  A  striking feature of the 
known binding sites for SH3  domains is the frequency of 
proline residues (32). The sequence requirements for inter- 
actions with the SH3  domains of most proteins, including 
p56  lck, are  not  known.  Yu  et  al.  (39)  recently screened  a 
9-mer  combinatorial  peptide  library in  order  to  identify 
amino  acid sequences  that  can  bind  the  SH3  domain  of 
p60 src. The library, which was in the form  of XXXPPX- 
PXX, was biased to include a common PPXP  motif. Two 
classes ofpeptides bound to the Src SH3 domain. All mem- 
Table  1.  IL-2 Production (pg/ml) in Full-Length CD2 and CY49.69Jurkat  Clones after Stimulation with Anti-Rat  CD2 (0X-54 and 
0X-55) or Anti-TCR mAb (C305) 
Experiment 1  Experiment 2 
Clone  PMA  CD2 +  PMA  TC1K +  PMA  PMA  CD2 +  PMA  TC1K +  PMA 
Full-length  < 10  392  641  < 10  > 1,500  1,570 
CY49.69  <10  835  707  <10  407  848 
106 cells were stimulated overnight with PMA (10 ng/ml) alone, anti-rat CD2 mAb (25 mg/ml of OX-54 and OX-55) plus PMA, or anti-TCR 
mAb (1:500 dilution from C305 ascites) plus PMA. Culture supernatants were assayed  for IL-2 as described in Materials and Methods. Data presented 
are representative of at least four independent  experiments. At least two separate clones for each construct were evaluated. 
175  Bell et al. bers of the first group had an R_XL motif at the amino ter- 
minus and a leucine  at position 6;  the majority had a basic 
amino  acid,  usually  arginine,  at  the  penultimate  position 
and  a  hydrophobic  amino  acid  at  the  carbox  3"  terminus. 
Peptide  2  from the  CD2  cytoplasmic  domain  also  has  an 
amino  terminal  RXL motif and an arginine  at the  equiva- 
lent  of the  penultimate  position  of the  library peptide.  In 
the CD2 sequence  this arginine  (which is the COOH  ter- 
minus  of peptide  2)  is followed by a  hydrophobic  residue. 
Peptide  4  contains  the  motif PPLPR,  which  is  the  com- 
mon feature of the second class  of Src SH3  domain-bind- 
ing  peptides.  Thus,  both  CD2  sequences  that  bind  p56  kk 
share key features with peptides selected for their abili b- to 
bind to the SH3 domain of a closely related PTK, p60Srq In 
contrast,  analysis  of the  other  proline-rich  sequences  in 
CD2 fails to reveal similarities between these sequences and 
the Src SH3 domain-binding peptides. 
By interacting with the SH3 domain of p56 kk, CD2 may 
influence the enzymatic activity of this PTK.  Phosphoryla- 
tion ofa COOH-ternfinal  tyrosine residue (tyrosine 505 in 
p56 l~k) down  regulates  the  activity of Src-like  PTKs  (40). 
The phosphory,  lated COOH-ternfinal  tyrosine likely binds 
to the SH2 domain of the kinase,  causing the PTK to fold 
back on itself and rendering the kinase inactive.  It has been 
proposed that an interaction between the SH3 domain and 
a proline-rich  region in the COOH  terminus of p56 kk fur- 
ther stabilizes this "closed" conformation  (41). Indeed, nm- 
tations in the SH3 domain of Src-like PTKs, which would 
prevent this interaction,  increase kinase activity (40). When 
p56 Ick binds to CD2,  its SH3 domain is occupied,  prevent- 
ing it from interacting  with  the  COOH-tem~inal  proline- 
rich region of p56 I&. This may destabilize the inactive con- 
formation of p56 lck and favor an  "open"  or active form of 
the kinase.  It is possible,  therefore,  that there  is an impor- 
tant  qualitative  difference  between  CD2-associated  p56 kk 
and  the  p56 lck associated  with  receptors,  such  as  CD4  or 
CD8,  that, by interacting with the unique  region of p56 kk, 
should  not  affect  the  stability  of the  inactive  form  of the 
enzyme (42, 43). 
Previous studies by several investigators have focused on 
the potential importance of proline-rich  sequences  for sig- 
naling by human CD2  (21, 36, 37).  Mutants with as few as 
the first 77  an-fino acids of the  cytoplasnfic domain  of hu- 
man CD2 were capable of coupling to a rise in [Ca2+]i and 
IL-2 production,  whereas  truncations  to  ~<43  amino  acids 
failed to  couple  to signaling pathways,  suggesting  that  the 
region  between  amino  acids  43  and  77  was  required  for 
CD2 signal transduction  (21). This region contains  the first 
two  proline-rich  domains.  Mutational  analysis  of this  re- 
gion has led to conflicting results.  Chang  et al.  (37)  found 
that substitution  of the HR  with DE af}er the first proline- 
rich region, but not the second,  resulted in a loss of signal- 
ing  by  CD2.  Alternatively,  when  Hahn  and  Bierer  (36) 
made the same mutation,  they failed to detect a  change in 
IL-2  production  after  CD2  stimulation.  Internal  deletion 
mutants excising either of the PPPGHR,  motifs in the first 
and  second  proline-rich  regions  reduced  CD2-mediated 
IL-2 production,  and deletion of this motif in both regions 
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resulted  in  complete  abrogation  of CD2-mediated  IL-2 
production  (36).  Consistent  with  the  findings  presented 
above, an internal deletion lacking amino acids 19-77 of the 
cytoplasmic tail of human CD2 also failed to produce  IL-2 
in response to CD2 stimulation  (36). 
In our experiments, deletion of the first and second pro- 
line-rich  regions  (CY49.69)  had  little  if any effect on  the 
ability of CD2 to couple to a rise in [Ca2+]i or to IL-2 pro- 
duction.  Although  the  rat  and  human  sequences  differ 
slightly in the first two proline-rich  regions,  they are iden- 
tical in the fourth and fifth proline-rich  regions (amino ac- 
ids 80-103  in the human), suggesting that a constrnct com- 
parable  to  our  CY49.69  in  the  hmnan  would  signal.  The 
reason for the discrepancy between our results and those of 
Hahn  and  Bierer  (36)  may  lie  in  the  way  the  constructs 
were made.  One  of Hahn and Bierer's constructs  retained 
the  sequences  between  the  proline-rich  domains  and  the 
other  excised  a  larger  portion  of the  cytoplasmic  domain 
than  our  CY49.69.  This  may  have  resulted  in  secondary- 
structural  changes  that  prevented  the  fourth  proline-rich 
region from binding p56 Ick. 
Our studies  indicate  that specific proline-rich  regions in 
the  COOH-ternfinal  half of the  cytoplasmic  domain  of 
CD2  mediate the direct interactions  of CD2  and p56 kk by 
binding the SH3 domain of p56 lck. Carmo et al. (13), how- 
ever,  have  shown  that p56 lck is present  in  CD2  immuno- 
precipitates  from  the  CY40  mutant  expressed  in  Jurkat. 
These immunoprecipitations  were performed using Brij 96 
lysates. It is possible that the proximal 40 amino acids in the 
cytoplasmic domain of CD2 may associate with other mol- 
ecules that mediate an association with p56 lck and that these 
associations  are  not  maintained  in  the  conditions  we  used 
for our studies  (1%  NP-40  lysis buffer).  Our  studies  indi- 
cate that  the  first 40  amino  acids  do  not participate  in  the 
direct binding to p56 lck. Neither our CY40 truncation nm- 
tant  nor  our  T7-40  fusion  protein  coprecipitated  with 
GST/p56 kk.  Additionally,  our  7.41  internal  deletion  mu- 
tant,  which  lacks anfino  acids 7-4l  of the  cytoplasnfic  tail 
of CD2,  consistently bound p56 kk better than F.L.  CD2. 
Because  the  CD2  sequences  that  bind  the  p56  kk  SH3 
domain  resemble  the  consensus  sequences  for binding  the 
p60 s~ SH3 domain, interactions  between CD2 and the Src 
family may not be limited to p56 I~k but may involve other 
members as  well.  Several observations  indicate  that  this  is 
likely the case. Both p596'" and p56 kk coinmmnoprecipitate 
with CD2 fi'om T  cells and NK cells, raising the possibility 
that  p596"  directly  interacts  with  CD2  (13,  14,  27).  We 
also have fbund  that another Src-like kinase,  p54bn  coim- 
munoprecipates  with  CD2  when  the  latter is  expressed in 
I~I3L, a  rat  basophilic  leukemia  line  that  does  not  express 
p56 I&  (G.  Bell;  unpublished  observations).  We  are  cur- 
rently investigating whether the SH3 domains ofp596'" and 
p54 ly" mediate  these  interactions  with  CD2  and  whether 
they bind the same CD2 sequences as p56 kk. 
Although  our results are consistent with a role for p56 l& 
in  CD2-mediated  signaling,  we  cannot  conclude  that  the 
association  with  p56 k'k is  sufficient  or  even  necessary-  for 
CD2  signaling.  An interesting  possibility,  not addressed  in our  study,  is that  signaling molecules other  than  the  Src- 
like PTKs interact with CD2  using a mechanism similar to 
the one described here. Of note in this regard, the peptide 
corresponding  to  the  first proline-rich region  (peptide  1) 
binds p56  l~k poorly and does not resemble the Src SH3 do- 
main-binding peptides.  Nevertheless,  deletion of this  re- 
gion in human CD2 results in a  10-fold reduction of CD2- 
mediated IL-2 production  (36).  One possibility is that this 
proline-rich region binds to  the  SH3  domain of signaling 
molecule,  other  than  a  Src-like PTK,  which  may be  re- 
quired for CD2-mediated signal transduction. 
CD2-mediated  signaling  requires  the  presence  of the 
TCR  or of receptors that contain members of the TCR 
chain family (16, 44).  Perturbation of CD2 on T  cells leads 
to the tyrosine phosphorylation of the TCR.-/~ chain, and it 
is likely that this event is crucial for CD2 signaling (20, 26). 
Tyrosine  phosphorylation  triggers an  association between 
TC1K-~ and ZAP70, a  PTK thought  to play a critical role 
in TC1K signaling (45). As noted above, CD2 appears to be 
in  physical proximity with  the  TCR  and,  under  certain 
conditions, TC1K-~ coimmunoprecipitates with CD2  (12). 
The demonstration that CD2 associates with p56  lck suggests 
that, like the CD4  and CD8  coreceptors, CD2  may bring 
p56  kk into  proximity with  potential substrates  within  the 
TC1K  complex.  Furthermore,  the  mechanism  by  which 
CD2 associates with p56 kk may make CD2 uniquely suited 
to stimulate the phosphorylation of TCR  components. 
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